OPTIMAL ANTAGONISM OF GPIIB IIIA FAVORS PLATELET-ADHESION BY INHIBITING THROMBUS GROWTH - AN EX-VIVO CAPILLARY PERFUSION CHAMBER STUDY IN THE GUINEA-PIG/
P. Andre et al., OPTIMAL ANTAGONISM OF GPIIB IIIA FAVORS PLATELET-ADHESION BY INHIBITING THROMBUS GROWTH - AN EX-VIVO CAPILLARY PERFUSION CHAMBER STUDY IN THE GUINEA-PIG/, Arteriosclerosis, thrombosis, and vascular biology, 16(1), 1996, pp. 56-63
To evaluate the involvement of the glycoprotein (GP) IIb/IIIa-dependen
t process in platelet deposition and thrombus growth on capillaries co
ated with human type III collagen, the effects of incremental doses of
Lamifiban, a potent specific synthetic GPIIb/IIIa antagonist, were st
udied in ex vivo capillary perfusion chambers using guinea pig blood.
In this model, nonanticoagulated blood was perfused for 4.5 minutes at
three shear rates: 100, 650, and 1600 s(-1). Platelet deposition was
quantified by computer-assisted morphometry and expressed as platelet
adhesion (percentage of capillary surface covered with spread and cont
act platelets and platelets implicated in thrombus), mean thrombus hei
ght; and total thrombus cross-sectional area. In control untreated gui
nea pigs, platelet adhesion and thrombus height were 63% and 2.5 mu m
at 100 s(-1), 60.5% and 13.5 mu m at 650 s(-1), and 45% and 28.1 mu m
at 1600 s(-1), respectively. At 100 s(-1), Lamifiban had no effect on
platelet deposition at any of the three doses administered to the guin
ea pigs (0.3, 1, and 3 mg/kg). At 0.3 mg/kg and shear rates of 650 and
1600 s(-1), Lamifiban had no effect on platelet adhesion or thrombus
size, but at 1 and 3 mg/kg and shear rates of 650 and 1600 s(-1), it s
ignificantly reduced thrombus size. At 1600 s(-1), 1 mg/kg Lamifiban s
ignificantly increased platelet adhesion from 45% to 62.5%, whereas at
3 mg/kg it induced a significant overall decrease from 45% to 25% and
qualitatively increased the ratio of contact to spread platelets. The
se data suggest that at high shear rates, GPIIb/IIIa participates in p
latelet spreading and that there is a balance between platelet involve
ment in adhesion to the thrombogenic surface and the growth of the alr
eady formed thrombus. This indicates that important clinical implicati
ons of an optimal therapeutic degree of GPIIb/IIIa antagonism could be
expected.